OpenArc Corporate Advisory’s Arcutis Biotherapeutics ARQT Stock Holding History

OpenArc Corporate Advisory’s Portfolio ARQT Stock Details ARQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$805K	Buy	30,700 +107	+0.3%	+$2.49K	0.01%	384
2026 Q1	$721K	Sell	30,593 -8	-0%	-$204	0.01%	374
2025 Q4	$889K	Buy	+30,601	New	+$783K	0.01%	312

Other funds holding ARQT

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

OpenArc Corporate Advisory's ARQT Position: Q2 2026 in Review

OpenArc Corporate Advisory increased its Arcutis Biotherapeutics (ARQT) stake by 0.35% in Q2 2026, buying an estimated $2.49K and bringing the position to 30,700 shares worth $805K. The position accounts for 0.01% of the portfolio, ranked #384.

OpenArc Corporate Advisory first reported a position in ARQT in Q4 2025 and has held it in 3 quarters since. The position peaked at $889K in Q4 2025. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

OpenArc Corporate Advisory held 30,700 shares of Arcutis Biotherapeutics worth $805K as of Q2 2026.
OpenArc Corporate Advisory bought 107 Arcutis Biotherapeutics shares in Q2 2026, an estimated $2.49K.
Arcutis Biotherapeutics made up 0.01% of OpenArc Corporate Advisory's portfolio in Q2 2026, its #384 holding.
OpenArc Corporate Advisory first reported a position in Arcutis Biotherapeutics in Q4 2025 and has held it in 3 quarters since.
OpenArc Corporate Advisory's Arcutis Biotherapeutics position peaked at $889K in Q4 2025.
272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on OpenArc Corporate Advisory's 13F filing for Q2 2026, filed 5 Aug 2026.